This agenda is from the 2018 show. The 2019 agenda is to be announced closer to the show.
Wednesday 6th June
Thursday 7th June
11.00 - 11.30
Dr Peter Smielewski
New advances in Transcranial Doppler ultrasound have now made it possible to obtain continuous measurements of cerebral blood flow waveforms over prolonged periods of time, measured in hours (or possibly days) rather than minutes. This opens new possibilities for application of TCD to pathologies like acute traumatic brain injury, where single, daily measurements are not sufficient to keep up with their highly dynamic character. When TCD cerebral blood flow velocity measurement is combined with measurement of arterial blood pressure waveform a purpose designed software can extract many parameters helping to track the status of cerebral autoregulation and other cerebrovascular properties like critical closing pressure (arterial pressure at which cerebral flow ceases) and critical closing margins (a ‘safety cushion’ for blood pressure). These in turn, when examined, for example, against intracranial pressure may help to inform selection of individual targets for TBI in ICU, thus aiding in personalised medicine approach.
11.45 - 12.15
Mr James Cooper & Ali Gibson
The PReSUTINeB study is a double blinded, placebo controlled study assessing if an immunotherapy treatment, in the form of an oral capsule, can reduce the incidence of symptomatic urinary tract infections in patients with spinal cord injury, multiple sclerosis, transverse myelitis and cauda equina syndrome. The intervention started in March 2018. The seminar will also include a short talk from the SMSR Community Liaison Officer Ali Gibson who will discuss her first-hand experience with symptomatic urinary tract infections and how this impacts her quality of life.
12.30 - 13.00
Dr Kyriaki Paroutoglou
Greater Manchester Connected Health Cities use technology and data to improve the diagnosis and treatment of stroke. In GM anything up to 50% of patients taken to a hyper-acute stroke ward are not actually having a stroke, they are having a stroke mimic. At Salford Royal we are using data to improve the recognition of stroke by paramedics so to minimise the number of non-stroke patients entering the stroke pathway. This seminar will discuss how we are linking historical ambulance data with data from Salford Royal Foundation Trust to identify false positive cases (stroke mimics) and explore how such situations may arise. Changes can then be put in place to ensure patients go to the right place, at the right time for the right care.
13.15 - 13.45
Rosalie E Ferner
An overview of the diagnosis, surveillance and management of neurofibromatosis 1, Neurofibromatosis 2 and schwannomatosis
14.00 - 14.30
This seminar will cover the background to ketogenic dietary therapy, practical implementation of the different variants of diet, and efficacy data supporting their use in both children and adults with intractable seizures. The potential of this therapy in other neurological conditions beyond epilepsy will also be explored.
14.45 - 15.15
Intellectual Property (IP) is in every part of your business – from product development to manufacturing. The IP audit and the IP strategy are two key management tools that can support your business plans ensuring you are prepared for investors when they are considering investing in your business. An IP audit helps you identify what assets you have, their protection status, where you are using them along with any legal issues. An IP strategy considers your commercial goals detailing how you are managing your IP assets and handling any threats to it, such as infringements or competitors. In this session we will use practical, day to day examples helping you identify red flags in your audit and giving ideas on how to create a robust strategy. These will help you discover new ways to capitalise on them and make better strategic business decisions when it comes to leveraging new opportunities.
15.30 - 16.00
Empatica is a full-stack company building medical and research devices specialized for neurology: we develop technology that improves people’s lives. Embrace is the world's first smart watch to be cleared by FDA for use in Neurology.